Menopause and Lung Health: Physiological Changes, Disease Risks, and Clinical Management

Menopause is usually discussed in relation to hot flushes, sleep, bone health, and cardiovascular risk. Its potential effects on the respiratory system deserve attention, too. Emerging research suggests that changes in reproductive hormones during the menopausal transition may influence breathing mechanics, lung-function decline, airway inflammation, and the clinical expression of respiratory conditions. The relationship, however, is complex: menopause does not automatically cause lung disease, and many observed associations cannot be separated completely from aging, smoking, body composition, or other health factors.

A 2026 narrative review by Aktoz and colleagues brings these questions together, examining sex hormones, pulmonary physiology, asthma, chronic obstructive pulmonary disease (COPD), lung cancer, and menopausal hormone therapy (MHT).[1] This article synthesizes that review’s publicly available abstract alongside accessible primary studies, systematic reviews, and clinical guidance. It is an educational narrative review, not a systematic review or an individualized treatment recommendation.

Why menopause matters to respiratory health

Natural menopause marks the end of menstrual cycles as ovarian reproductive activity declines. Estrogen and progesterone levels change substantially during the transition; androgen concentrations also change with age, although they do not follow the same abrupt trajectory. These hormones have receptors and biological effects beyond the reproductive system, including in airway smooth muscle, immune cells, lung tissue, and the vascular system.[1,2]

Several mechanisms may connect reproductive aging with respiratory changes:

• Airway regulation: Sex hormones may influence airway smooth-muscle tone and responsiveness, with effects that depend on hormone concentration, receptor signaling, and inflammatory context.
• Inflammatory signaling: Estrogens and progesterone interact with immune pathways; their effects can be protective or pro-inflammatory depending on the experimental model and disease phenotype.
• Lung and chest-wall mechanics: Menopause coincides with changes in body composition, muscle strength, bone health, and, in some individuals, spinal curvature or vertebral fracture, all of which may influence breathing mechanics.
• Comorbid conditions: Obesity, sleep-disordered breathing, cardiovascular disease, and deconditioning can contribute to breathlessness in midlife and later life.

These are plausible biological pathways, not proof that any individual respiratory complaint is caused by hormone deficiency.[1,2,3]

Does lung function decline faster after menopause?

The most consistent epidemiological signal concerns spirometry, particularly forced vital capacity (FVC)—the total volume forcibly exhaled after a maximal inhalation—and forced expiratory volume in one second (FEV1)—the volume exhaled in the first second.

In the longitudinal European Community Respiratory Health Survey, Triebner and colleagues analyzed repeated lung-function measurements and reproductive-health data from 1,438 women. Compared with women still menstruating regularly, the adjusted additional annual decline was approximately:

These figures describe differences in the rate of decline, not total annual loss, and should not be interpreted as a prediction for an individual patient. The stronger association with FVC suggests a predominantly non-obstructive pattern in this cohort.[4]

A subsequent systematic review by McLaughlin and colleagues, which included 10 publications, likewise found that available studies generally supported an association between menopause and lower lung function in a non-obstructive pattern. The authors emphasized uncertainty arising from age, metabolic changes, and MHT exposure.[3]

Clinical interpretation: A lower FVC does not by itself establish restrictive lung disease. True restriction requires assessment of total lung capacity when clinically indicated. Spirometry results must be interpreted using appropriate reference values, test quality, symptoms, and relevant exposures.

Asthma during the menopausal transition

Asthma is characterized by variable respiratory symptoms and variable expiratory airflow limitation. Because asthma prevalence, symptom patterns, and severity vary across reproductive life, researchers have investigated whether changing sex-hormone levels contribute to asthma onset or worsening around menopause.[2,5]

Individual experiences differ. Some people with existing asthma report more symptoms or exacerbations during midlife, while others notice little change. Importantly, menopause has not been shown consistently to increase asthma incidence in all women.

A 2012 systematic review and meta-analysis considered eight eligible studies and pooled six. It did not identify a statistically significant overall association between menopausal status and asthma. In analyses stratified by MHT, women reporting hormone therapy showed a modestly higher asthma association (relative risk 1.32, 95% confidence interval 1.01–1.74); this does not prove the therapy caused asthma.[5]

The French E3N cohort also investigated postmenopausal hormone exposure and adult-onset asthma, adding to concerns that formulation and patient characteristics may matter.[6] Observational studies can be affected by differences in healthcare use, pre-existing disease, body mass index, smoking, and reasons for prescribing MHT.

For patients with new wheezing, recurrent cough, chest tightness, or episodes of breathlessness, clinicians should use objective diagnostic assessment rather than attributing symptoms to menopause. The 2026 Global Initiative for Asthma (GINA) strategy emphasizes confirming asthma with a characteristic symptom pattern and evidence of variable expiratory airflow limitation whenever possible.[7]

COPD and persistent respiratory symptoms

COPD involves persistent airflow obstruction, most commonly associated with tobacco smoke, household or occupational inhalational exposures, and other individual risk factors. Menopause may coincide with increased reports of breathlessness, cough, or sputum, but more symptoms do not necessarily mean more COPD.[1,3]

The evidence directly connecting menopausal status to new COPD diagnoses remains limited. Published reviews highlight the difficulty of disentangling reproductive aging from cumulative exposure to tobacco smoke, age-related changes in lung function, and metabolic risk factors.[1,3,8]

When COPD is suspected, clinical evaluation should include an exposure and symptom history and post-bronchodilator spirometry. Under the 2026 Global Initiative for Chronic Obstructive Lung Disease (GOLD) framework, a post-bronchodilator FEV1/FVC ratio below 0.70, in a compatible clinical context, confirms persistent airflow obstruction; borderline results require careful clinical interpretation.[9]

The practical lesson is that persistent breathlessness in midlife deserves investigation. Depending on the history, alternative or coexisting explanations may include asthma, anemia, cardiovascular disease, obesity, sleep apnea, medication effects, or physical deconditioning.

Lung cancer: what is known about hormonal influences?

Lung cancer risk is driven predominantly by factors such as tobacco exposure and other environmental, occupational, and genetic risks. Researchers have nevertheless explored hormone-related pathways because estrogen receptors and hormone-processing enzymes are present in lung tissues and some lung tumors.[1,2,8]

Much of the human evidence is observational and inconsistent. One important exception is a post-hoc analysis of the randomized Women’s Health Initiative trial of combined conjugated equine estrogens and medroxyprogesterone acetate. Across the studied follow-up, lung cancer diagnoses were numerically higher in the combined-therapy group (109 versus 85), but the overall incidence difference was not statistically significant (hazard ratio 1.23, 95% confidence interval 0.92–1.63). The analysis raised a more concerning signal for lung-cancer mortality, especially non-small-cell lung cancer.[10]

Those findings should not be generalized to all contemporary MHT regimens, routes, doses, or durations. Nor do they establish that menopause itself causes lung cancer. The appropriate preventive priority remains smoking avoidance and cessation, reducing relevant exposures, and assessing eligibility for lung-cancer screening according to applicable local guidelines and personal risk.

Can menopausal hormone therapy protect the lungs?

MHT is effective for important menopausal indications, especially bothersome vasomotor symptoms, but evidence is insufficient to prescribe MHT specifically to preserve lung function or prevent respiratory disease.[1,8,11]

Research suggests potentially competing effects. Hormonal pathways may influence airway relaxation and inflammatory regulation; observational studies have also reported associations between MHT exposure and asthma outcomes, with results varying by study and regimen.[5,6,8] Similarly, research on lung cancer cannot be reduced to a simple claim that estrogen is protective or harmful.[10]

The Menopause Society’s 2022 position statement recommends individualized decisions based on symptoms, age, time since menopause, medical history, contraindications, regimen, and route. It notes that the benefit–risk profile is generally more favorable for appropriately selected symptomatic women younger than 60 years or within 10 years of menopause onset, while emphasizing regular reassessment.[11]

For someone with asthma or COPD, MHT decisions should be coordinated with the clinician managing menopause and, if needed, a respiratory specialist. MHT is not a substitute for evidence-based inhaled therapy or other indicated respiratory treatment. There is also no established clinical role for androgen therapy solely to improve lung health after menopause.[1,2]

Clinical management: an integrated approach

A practical approach is to treat menopausal stage as context, not as an automatic diagnosis.

1. Ask specifically about respiratory symptoms

At midlife healthcare visits, asking about exertional breathlessness, wheeze, cough, sputum production, nighttime breathing problems, and exercise tolerance can identify symptoms that may otherwise be overlooked. Establish when symptoms began and whether they fluctuate, persist, or progress.

2. Review exposures and other risk factors

Document tobacco and vaping exposure, secondhand smoke, occupational dust or fumes, biomass smoke, prior respiratory disease, family history, medications, and relevant environmental exposure. Consider body composition, physical activity, cardiovascular risks, and sleep quality.

3. Use objective testing when indicated

Spirometry is appropriate for suspected asthma or COPD and for otherwise unexplained persistent respiratory symptoms. Additional studies—such as lung volumes, diffusing capacity, chest imaging, cardiac evaluation, or sleep testing—depend on clinical findings; they are not routine tests required for every menopausal patient.

4. Treat confirmed disease according to respiratory guidelines

Follow current GINA guidance for asthma and GOLD guidance for COPD, including appropriate inhaled treatments, inhaler-technique review, smoking cessation support, and relevant immunizations. Menopausal status does not replace standard diagnosis or treatment pathways.[7,9]

5. Support respiratory health through modifiable factors

Smoking cessation, regular physical activity, strength training, management of cardiometabolic conditions, and treatment of sleep disorders can support general health and respiratory function. Measures should be individualized for patients with established lung disease.

6. Assess hormone therapy on its established indications

Discuss MHT in relation to menopausal symptoms and the person’s overall benefit–risk profile. Current evidence does not support using a change in spirometry alone as an indication to start or stop MHT.[8,11]

Seek urgent medical attention for severe or sudden breathlessness, chest pain, coughing up blood, fainting, or low oxygen levels. New or progressive respiratory symptoms should not be dismissed as a normal consequence of menopause.

What the evidence still cannot answer

Despite growing interest, substantial gaps remain:

1. Causation: Longitudinal associations cannot fully separate hormonal change from chronological aging and other midlife exposures.
2. Disease subtypes: Asthma and COPD are heterogeneous; hormonal effects may differ by inflammatory phenotype, smoking history, and disease severity.
3. Timing and duration: The effects of early, natural, and surgical menopause—and time since menopause—need more consistent comparison.
4. Hormone formulations: Results from one oral estrogen–progestin regimen cannot automatically be transferred to transdermal estradiol or different progestogens.
5. Patient-centered outcomes: Studies need to connect physiological measurements with exacerbations, exercise capacity, quality of life, and long-term clinical outcomes.

Future research will be strongest when it combines repeated measures of reproductive stage, carefully measured hormone exposure, objective pulmonary outcomes, and adequate adjustment for confounding factors.[1–3,8]

Conclusion

Menopause may be a meaningful period for respiratory health. The clearest finding so far is an association between the menopausal transition and faster decline in lung function, especially FVC. Associations with asthma are inconsistent, direct evidence for COPD remains limited, and the implications of hormone therapy for lung cancer and other respiratory outcomes require careful interpretation.

For patients, the important message is not that menopause inevitably damages the lungs, but that persistent changes in breathing deserve recognition and appropriate evaluation. For clinicians, a sex- and life-stage-informed approach may help identify respiratory problems without confusing association with causation. Until stronger trials are available, prevention, objective diagnosis, guideline-based respiratory care, and individualized menopausal treatment remain the foundations of management.

References

1. Aktoz F, Erel CT, Ozcivit Erkan IB. Menopause and lung health: a narrative review of physiological changes, disease risks and clinical management. Climacteric. Published online October 9, 2026. doi:10.1080/13697137.2026.2735783. PubMed.
2. Silveyra P, Babayev M, Ekpruke CD. Sex, hormones, and lung health. Physiological Reviews. doi:10.1152/physrev.00026.2024.
3. McLaughlin J, et al. Menopause, lung function and obstructive lung disease outcomes: a systematic review. Climacteric. 2018;21(1):3–12. doi:10.1080/13697137.2017.1392504.
4. Triebner K, et al. Menopause is associated with accelerated lung function decline. American Journal of Respiratory and Critical Care Medicine. 2017;195(8):1058–1065. doi:10.1164/rccm.201605-0968OC.
5. Asthma and the menopause: a systematic review and meta-analysis. Maturitas. 2012;73(3):212–217. doi:10.1016/j.maturitas.2012.08.010.
6. Romieu I, et al. Postmenopausal hormone therapy and asthma onset in the E3N cohort. Thorax. 2010;65(4):292–297. doi:10.1136/thx.2009.116079.
7. Global Initiative for Asthma. 2026 Summary Guide for Asthma Management and Prevention. Official guidance.
8. Eliyahu E, et al. Effects of Hormone Replacement Therapy on Women’s Lung Health and Disease. Pulmonary Therapy. 2023;9:461–477. doi:10.1007/s41030-023-00240-0.
9. Global Initiative for Chronic Obstructive Lung Disease. 2026 GOLD Report and Pocket Guide. Official guidance.
10. Chlebowski RT, et al. Oestrogen plus progestin and lung cancer in postmenopausal women (Women’s Health Initiative trial): a post-hoc analysis of a randomised controlled trial. The Lancet. 2009;374(9697):1243–1251. doi:10.1016/S0140-6736(09)61526-9.
11. The North American Menopause Society Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767–794. doi:10.1097/GME.0000000000002028.

Editorial note: This article is a summary prepared from publicly accessible records and publications as of October 14, 2026. The full text and complete bibliography of the October 2026 Aktoz et al. review were not accessible, so this article does not claim to cover every study cited in that paper. It has not been reviewed by a clinician. See the editorial policy for how articles here are written and sourced.

• menopause
• women's health
• respiratory health
• lung function
• clinical review